Random biopsy: when, how many and where to take the cores?
- First Online:
- 379 Downloads
The optimal random prostate biopsy scheme (PBx) in the initial and repeated setting is still an issue of controversy. We performed an analysis of the recent literature about the prostate biopsy techniques.
We performed a clinical and critical literature review by searching MEDLINE database from January 2005 up to January 2014. Electronic searches were limited to the English language, and the keywords prostate cancer, prostate biopsy, transrectal ultrasound, transperineal prostate biopsy were used.
Prostate biopsy strategy in initial setting. According to the literature and the major international guidelines, the recommended approach in initial setting is still the extended scheme (EPBx) (12 cores). However, there is now a growing evidence in the literature that (a) saturation PBx (>20 cores) (SPBx) might be indicated in patients with PSA <10 ng/ml or low PSA density or large prostate and (b) an individualized approach with more than 12 cores according to the clinical characteristics of the patients may optimize cancer detection in the single patient. Moreover, in the era of multi-parametric MRI (mpMRI), EPBx or SPBX may be substituted by mpMRI-targeted biopsies that have demonstrated superiority over systematic random biopsies for the detection of clinically significant disease and representation of disease burden, while deploying fewer cores. Prostate biopsy strategy in repeat setting. How and how many cores should be taken in the different scenarios in the repeated setting is still unclear. SPBx clearly improves cancer detection if clinical suspicion persists after previous biopsy with negative findings and is able to provide an accurate prediction of prostate tumour volume and grade. Nevertheless, international guidelines do not strongly recommended SPBx in all situations of repeated setting. In the active surveillance and in focal therapy protocols, the optimal schemes have to be defined.
The course of PBx has changed significantly from sextant biopsies to systematic and from extended to SPBx schemes. The issue about the number and location of the cores is still a matter of debate both in initial and in repeat setting. At present, EPBx is sufficient in most of the cases to provide adequate diagnosis and prostate cancer characterization in the initial setting, while SPBx seems to be necessary in repeat setting. The PBx schemes are evolving also because the scenario in which a PBx is necessary is changing. Random prostate PBx do not represent the future, while imaging target biopsy are becoming more popular.
KeywordsProstate cancer Prostate biopsy Transrectal ultrasound Transperineal prostate biopsy
- 13.Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 350(22):2239–2246 (Erratum in: N Engl J Med 2004; 351 (14): 1470)PubMedCrossRefGoogle Scholar
- 26.Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719PubMedCrossRefGoogle Scholar
- 28.Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, Walton-Diaz A, Vourganti S, Truong H, Kruecker J, Merino MJ, Wood BJ, Choyke PL, Pinto PA (2013) Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 190(5):1721–1727PubMedCrossRefGoogle Scholar
- 29.Nelson AW, Harvey RC, Parker RA, Kastner C, Doble A, Gnanapragasam VJ (2013) Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy. PLoS One 8(2):e57480PubMedCentralPubMedCrossRefGoogle Scholar
- 30.Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Fütterer J, Bouwense S, van Oort I, Schröder F, Huisman H, Barentsz J (2012) Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 61(1):177–184PubMedCrossRefGoogle Scholar
- 39.Li YH, Elshafei A, Li J, Gong M, Susan L, Fareed K, Jones JS (2013) Transrectal saturation technique may improve cancer detection as an initial prostate biopsy strategy in men with prostate-specific antigen <10 ng/ml. Eur Urol. doi:10.1016/j.eururo.2013.05.047
- 41.Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A et al (2008) Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 101(12):1513–1518PubMedCrossRefGoogle Scholar
- 44.Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, Fujii Y, Yonese J, Masuda H, Kihara K et al (2008) Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 54(3):601–611PubMedCrossRefGoogle Scholar
- 48.Scattoni V, Raber M, Capitanio U, Abdollah F, Roscigno M, Angiolilli D et al (2011) The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol 60(4):834–841PubMedCrossRefGoogle Scholar
- 52.Lane BR, Zippe CD, Abouassaly A, Schoenfield L, Magi-Galluzzi C, Stephen Jones L (2008) Saturation technique does not decrease cancer detection during follow-up after initial prostate biopsy. J Urol 179:1749–1750Google Scholar
- 70.Novara G, Boscolo-Berto R, Lamon C, Fracalanza S, Gardiman M, Artibani W, Ficarra V (2010) Detection rate and factors predictive the presence of prostate cancer in patients undergoing ultrasonography-guided transperineal saturation biopsies of the prostate. BJU Int 105(9):1242–1246PubMedCrossRefGoogle Scholar